EUVIMEDEUVIMED entdecken
Crossref

Absorption of naloxone in patients prescribed buprenorphine‐naloxone

Ian Michel, Domenic Ochal iD, Aniket Paharia, Paul Jannetto, Scott Breitinger, Tyler Oesterle

The American Journal on Addictions · 2025

DOI: 10.1111/ajad.13674 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal on Addictions, 2025. Verfasst von Ian Michel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Buprenorphine, Naloxone Drug Combination, Narcotic Antagonists, Naloxone, Buprenorphine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Mayo Clinic Kern Center for the Science of Health Care delivery, Terrance and Bette Noble Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives When administered as prescribed, the naloxone component of buprenorphine‐naloxone combination medications is putatively considered inert due to reduced naloxone bioavailability via transmucosal. However, there is a growing body of evidence to the contrary. The aim of our study is to determine the extent of naloxone absorption in a large cohort of patients receiving sublingual buprenorphine‐naloxone.

Methods

Using the Mayo Clinic Unified Data Platform, 425 patients prescribed sublingual buprenorphine/naloxone who received a controlled substance monitoring panel (CSMP) between January 1, 2022, and January 1, 2023 were identified and included. The CSMP is an immunoassay panel that confirms positive results quantitatively with gas chromatography mass spectrometry or liquid chromatography tandem mass spectrometry. This panel provides urinary detection for buprenorphine (cutoff: 5 ng/mL), naloxone (25 ng/mL), as well as their respective metabolites norbuprenorphine (5 ng/mL), norbuprenorphine‐glucuronide (20 ng/mL), and naloxone‐glucuronide (100 ng/mL).

Results

Of our 425 patients, 76% had norbuprenorphine ( n = 323), and 77% had norbuprenorphine‐glucuronide ( n = 327) in their toxicology tests, respectively. Naloxone‐glucuronide was detected in 91% ( n = 294) of the specimens with norbuprenorphine and 88.7% ( n = 290) of the specimens with norbuprenorphine‐glucuronide. Conclusion and Scientific Significance To our knowledge, this is the largest study to date demonstrating the presence of naloxone metabolites in patients taking combined buprenorphine‐naloxone medications. The results of this study refute the notion that naloxone absorption is negligible when administered in sublingual preparations. Further research on how this absorption impacts medication usage, dosing, adherence, and side effects is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Buprenorphine, Naloxone Drug CombinationNarcotic AntagonistsNaloxoneBuprenorphineHumansMaleFemaleAdultMiddle AgedAdministration, SublingualOpioid-Related Disorders

Substanzen

Buprenorphine, Naloxone Drug CombinationNarcotic AntagonistsNaloxonenorbuprenorphineBuprenorphine

Autor:innen und Institutionen

  • Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Tulane University School of Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Domenic Ochal

Förderung

  • Mayo Clinic Kern Center for the Science of Health Care delivery
  • Terrance and Bette Noble Foundation
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Michel, I., Ochal, D., Paharia, A., Jannetto, P., Breitinger, S., & Oesterle, T. (2025). Absorption of naloxone in patients prescribed buprenorphine‐naloxone. The American Journal on Addictions. https://doi.org/10.1111/ajad.13674

Vancouver

Michel I, Ochal D, Paharia A, Jannetto P, Breitinger S, Oesterle T. Absorption of naloxone in patients prescribed buprenorphine‐naloxone. The American Journal on Addictions. 2025. doi:10.1111/ajad.13674

BibTeX
@article{Michel2025,
  author = {Michel, Ian and Ochal, Domenic and Paharia, Aniket and Jannetto, Paul and Breitinger, Scott and Oesterle, Tyler},
  title = {Absorption of naloxone in patients prescribed buprenorphine‐naloxone},
  journal = {The American Journal on Addictions},
  year = {2025},
  doi = {10.1111/ajad.13674}
}
Kostenlos starten →